Submitted by: Submitted by HexaReport
Views: 10
Words: 941
Pages: 4
Category: Business and Industry
Date Submitted: 03/21/2016 02:05 AM
Hexa Reports
Market Research Reports and Insightful Company Profiles
Point of Care (PoC) Lipid Test Market Size, Share, Trend
Analysis, Market Growth By Technology Application And
Segment Forecasts To 2022
Global Point of care (PoC) Lipid Test market is expected to reach USD 280.02 million by 2022 according
to a new report by Grand View Research Inc. Growing geriatric population base, increasing global
prevalence of cardiovascular diseases, and rising healthcare awareness due to patient education are the
driving forces for the PoC Lipid Test industry growth during the forecast period.
Furthermore, continuous efforts by the government to reduce hospital stays and curb healthcare
expenditure, establishments attempting to provide effective and rapid diagnostic results, and
improvement in technology with the provision of cheap and high-quality medical solutions aimed at
achieving lab automation are some factors contributing to the growth of the PoC Lipid Test market.
Browse Detail Report With TOC @
http://www.hexareports.com/report/point-of-care-poc-lipid-test-market/details
Further key findings from the study suggest:
Alere Cholestech LDx market was estimated at over 6,400 units in 2014 and is expected to reach over
11,000 units by 2022, growing at a CAGR of 7.8% over the forecast period. The analyzer is included in
Hexa Reports
Market Research Reports and Insightful Company Profiles
the CLIA waived test list and is certified by the Cholesterol Reference Method Laboratory Method
Network (CRMLN) program and Lipid Standardization Program (LSP)
Global launch of Roche Cobas b 101 at the end of 2013 excluding the U.S. region and the introduction of
Samsung LABGEO PT10 in the Indian market are expected to drive the point of care Lipid Test market at
a lucrative rate over the next six years
Consumables Piccolo Express by Abaxis market was valued over 1,000 thousand units in 2014 owing to
the presence of CLIA-waived capillary or venous lipid and liver panel used for...